Denosumab for the Management of Postmenopausal Osteoporosis

References

• . National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation; 2008
   Google Scholar
• . NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285(6):785–795
   PubMed Web of Science ®Google Scholar
• . US Department of Health and Human Services. Bone health and osteoporosis: a report of the surgeon general. Rockville, MD: US Department of Health and Human Services, Office of the Surgeon General; 2004
   Google Scholar
• . National Osteoporosis Foundation. America's bone health: the state of osteoporosis and low bone mass in our nation. Washington, DC: National Osteoporosis Foundation; 2002
   Google Scholar
• . International Society for Clinical Densitometry. 2007 official positions of the International Society for Clinical Densitometry. West Hartford, CT: International Society for Clinical Densitometry; 2007
   Google Scholar
• . American College of Obstetricians and Gynecologists, Women's Health Care Physicians. Osteoporosis ACOG practice bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 50, January 2003. Obstet Gynecol. 2004;103(1):203–216
   PubMedGoogle Scholar
• . World Health Organization. Prevention and management of osteoporosis: WHO technical report series 921. Geneva, Switzerland: World Health Organization; 2003
   Google Scholar
• . North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17(1):25–54
   PubMed Web of Science ®Google Scholar
• . National Coalition for Osteoporosis and Related Bone Diseases. National action plan for bone health: recommendations from the Summit for a National Action Plan for Bone Health. Washington, DC: National Coalition for Osteoporosis and Related Bone Diseases; 2008
   Google Scholar
• . National Committee for Quality Assurance. HEDIS® 2009: Healthcare effectiveness data and information set. http://www.ncqa.org/Portals/0/Newsroom/SOHC/SOHC_2009.pdf. Accessed May 20, 2010
   Google Scholar
• . Foley KA, Foster SA, Meadows ES, Baser O, Long SR. Assessment of the clinical management of fragility fractures and implications for the new HEDIS osteoporosis measure. Med Care. 2007;45(9):902–906
   PubMed Web of Science ®Google Scholar
• . Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423(6937):337–342
   PubMed Web of Science ®Google Scholar
• . Abrams SA. Normal acquisition and loss of bone mass. Horm Res. 2003;60( suppl 3):71–76
   PubMedGoogle Scholar
• . Riggs BL, Khosla S, Melton LJ 3rd. Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev. 2002;23(3):279–302
   PubMed Web of Science ®Google Scholar
• . Anderson DM, Maraskovsky E, Billingsley WL, . A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature. 1997;390(6656):175–179
   PubMed Web of Science ®Google Scholar
• . Simonet WS, Lacey DL, Dunstan CR, . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. 1997;89(2):309–319
   PubMed Web of Science ®Google Scholar
• . Dougall WC, Glaccum M, Charrier K, . RANK is essential for osteoclast and lymph node development. Genes Dev. 1999;13(18):2412–2424
   PubMed Web of Science ®Google Scholar
• . Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998;188(5):997–1001
   PubMed Web of Science ®Google Scholar
• . Kong YY, Yoshida H, Sarosi I, . OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature. 1999;397(6717):315–323
   PubMed Web of Science ®Google Scholar
• . Lacey DL, Tan HL, Lu J, . Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000;157(2):435–448
   PubMed Web of Science ®Google Scholar
• . Lacey DL, Timms E, Tan HL, . Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998;93(2):165–176
   PubMed Web of Science ®Google Scholar
• . Li J, Sarosi I, Yan XQ, . RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism. Proc Natl Acad Sci. 2000;97(4):1566–1571
   PubMed Web of Science ®Google Scholar
• . Yasuda H, Shima N, Nakagawa N, . Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci. 1998;95(7):3597–3602
   PubMed Web of Science ®Google Scholar
• . Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC, Riggs BL. Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology. 1999;140(9):4367–4370
   PubMed Web of Science ®Google Scholar
• . D'Amelio P, Grimaldi A, Di Bella S, . Estrogen deficiency increases osteoclastogenesis up-regulating T cells activity: a key mechanism in osteoporosis. Bone. 2008;43(1):92–100
   PubMed Web of Science ®Google Scholar
• . Eghbali-Fatourechi G, Khosla S, Sanyal A, Boyle WJ, Lacey DL, Riggs BL. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women. J Clin Invest. 2003;111(8):1221–1230
   PubMed Web of Science ®Google Scholar
• . Hodgson SF, Watts NB, Bilezikian JP, ; AACE Osteoporosis Task Force.American Association of Clinical Endocrinologists medical guidelines for clinical practice for the prevention and treatment of postmenopausal osteoporosis: 2001 edition, with selected updates for 2003. Endocr Pract. 2003;9(6):544–564
   PubMedGoogle Scholar
• . Cooper C, Melton LJ 3rd. Epidemiology of osteoporosis. Trends Endocrinol Metab. 1992;3(6):224–229
   PubMed Web of Science ®Google Scholar
• . Burge R, Dawson-Hughes B, Solomon DH, Wong JB, King A, Tosteson A. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005–2025. J Bone Miner Res. 2007;22(3):465–475
   PubMed Web of Science ®Google Scholar
• . Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res. 2000;15(4):721–739
   PubMed Web of Science ®Google Scholar
• . Nevitt MC, Thompson DE, Black DM, . Effect of alendronate on limited-activity days and bed-disability days caused by back pain in postmenopausal women with existing vertebral fractures. Fracture Intervention Trial Research Group. Arch Intern Med. 2000;160(1):77–85
   PubMedGoogle Scholar
• . Papaioannou A, Watts NB, Kendler DL, Yuen CK, Adachi JD, Ferko N. Diagnosis and management of vertebral fractures in elderly adults. Am J Med. 2002;113(3):220–228
   PubMed Web of Science ®Google Scholar
• . Lindsay R, Silverman SL, Cooper C, . Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285(3):320–323
   PubMed Web of Science ®Google Scholar
• . Roux C, Fechtenbaum J, Kolta S, Briot K, Girard M. Mild prevalent and incident vertebral fractures are risk factors for new fractures. Osteoporos Int. 2007;18(12):1617–1624
   PubMed Web of Science ®Google Scholar
• . Cree M, Soskolne CL, Belseck E, . Mortality and institutionalization following hip fracture. J Am Geriatr Soc. 2000;48(3):283–288
   PubMed Web of Science ®Google Scholar
• . Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359(9319):1761–1767
   PubMed Web of Science ®Google Scholar
• . Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd. Population-based study of survival after osteoporotic fractures. Am J Epidemiol. 1993;137(9):1001–1005
   PubMed Web of Science ®Google Scholar
• . Leibson CL, Tosteson AN, Gabriel SE, Ransom JE, Melton LJ. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc. 2002;50(10):1644–1650
   PubMed Web of Science ®Google Scholar
• . Magaziner J, Lydick E, Hawkes W, . Excess mortality attributable to hip fracture in white women aged 70 years and older. Am J Public Health. 1997;87(10):1630–1636
   PubMed Web of Science ®Google Scholar
• . Haentjens P, Magaziner J, Colon-Emeric CS, . Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med. 2010;152(6):380–390
   PubMed Web of Science ®Google Scholar
• . Habib ZA, Havstad SL, Wells K, Divine G, Pladevall M, Williams LK. Thiazolidinedione use and the longitudinal risk of fractures in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2010;95(2):592–600
   PubMed Web of Science ®Google Scholar
• . Meier C, Kraenzlin ME, Bodmer M, Jick SS, Jick H, Meier CR. Use of thiazolidinediones and fracture risk. Arch Intern Med. 2008;168(8):820–825
   PubMed Web of Science ®Google Scholar
• . Gray SL, LaCroix AZ, Larson J, . Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. Arch Intern Med. 2010;170(9):765–771
   PubMedGoogle Scholar
• . Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008;179(4):319–326
   PubMed Web of Science ®Google Scholar
• . Kanis JA, Borgstrom F, De Laet C, . Assessment of fracture risk. Osteoporos Int. 2005;16(6):581–589
   PubMed Web of Science ®Google Scholar
• . Wainwright SA, Marshall LM, Ensrud KE, ; Study of Osteoporotic Fractures Research Group. Hip fracture in women without osteoporosis. J Clin Endocrinol Metab. 2005;90(5):2787–2793
   PubMed Web of Science ®Google Scholar
• . Siris ES, Chen YT, Abbott TA, . Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164(10):1108–1112
   PubMedGoogle Scholar
• . World Health Organization. FRAX: WHO Fracture Risk Assessment Tool. http://www.shef.ac.uk/FRAX/index.htm. Accessed January 21, 2010
   Google Scholar
• . Ettinger B, Ettinger KM. FRAX: Using the new fracture risk assessment tool. Contemporary OB/GYN. 2009;54(7):22–28
   Google Scholar
• . Watts NB, Lewiecki EM, Miller PD, Baim S. National Osteoporosis Foundation 2008 Clinician's Guide to Prevention and Treatment of Osteoporosis and the World Health Organization Fracture Risk Assessment Tool (FRAX): what they mean to the bone densitometrist and bone technologist. J Clin Densitom. 2008;11(4):473–477
   PubMed Web of Science ®Google Scholar
• . Roux C, Thomas T. Optimal use of FRAX. Joint Bone Spine. 2009;76(1):1–3
   PubMed Web of Science ®Google Scholar
• . Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc. 2002;77(5):453–468
   PubMed Web of Science ®Google Scholar
• . Odabasi E, Turan M, Tekbas F, Kutlu M. Evaluation of secondary causes that may lead to bone loss in women with osteoporosis: a retrospective study. Arch Gynecol Obstet. 2009;279(6):863–867
   PubMed Web of Science ®Google Scholar
• . Tannenbaum C, Clark J, Schwartzman K, . Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87(10):4431–4437
   PubMed Web of Science ®Google Scholar
• . Luckey M, Tannenbaum C. Authors' response: recommended testing in patients with low bone density. J Clin Endocrinol Metab. 2003;88(3):1402–1405
   Web of Science ®Google Scholar
• . National Osteoporosis Foundation. Physician's prevention and treatment of osteoporosis. Washington, DC: National Osteoporosis Foundation; 2003
   Google Scholar
• . Dawson-Hughes B, Tosteson AN, Melton LJ 3rd, ; National Osteoporosis Foundation Guide Committee. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporos Int. 2008;19(4):449–458
   PubMed Web of Science ®Google Scholar
• . Guideline for the prevention of falls in older persons. American Geriatrics Society, British Geriatrics Society, and American Academy of Orthopaedic Surgeons Panel on Falls Prevention. J Am Geriatr Soc. 2001;49(5):664–672
   PubMed Web of Science ®Google Scholar
• . Bonura F. Prevention, screening, and management of osteoporosis: an overview of the current strategies. Postgrad Med. 2009;121(4):5–17
   PubMed Web of Science ®Google Scholar
• . American Society for Bone and Mineral Research. American Society for Bone and Mineral Research statement on potential cardiovascular risks associated with calcium supplements. August, 12, 2010
   Google Scholar
• . Recker RR, Lewiecki EM, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122( 2 suppl):S22–S32
   PubMed Web of Science ®Google Scholar
• . Solomon DH, Rekedal L, Cadarette SM. Osteoporosis treatments and adverse events. Curr Opin Rheumatol. 2009;21(4):363–368
   PubMed Web of Science ®Google Scholar
• . Silverman SL, Landesberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122( 2 suppl):S33–S45
   PubMed Web of Science ®Google Scholar
• . Cooper A, Drake J, Brankin E; PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract. 2006;60(8):896–905
   PubMed Web of Science ®Google Scholar
• . Cotte FE, Fardellone P, Mercier F, Gaudin AF, Roux C. Adherence to monthly and weekly oral bisphosphonates in women with osteoporosis. Osteoporos Int. 2010;21(1):145–155
   PubMed Web of Science ®Google Scholar
• . Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL. Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med. 2009;122( 2 suppl):S3–13
   PubMed Web of Science ®Google Scholar
• . Prolia™ (denosumab) [package insert]. Thousand Oaks, CA: Amgen Inc; 2010
   Google Scholar
• . Bekker PJ, Holloway DL, Rasmussen AS, . A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res. 2004;19(7):1059–1066
   PubMed Web of Science ®Google Scholar
• . Kostenuik PJ, Nguyen HQ, McCabe J, . Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL. J Bone Miner Res. 2009;24(2):182–195
   PubMed Web of Science ®Google Scholar
• . Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol. 2005;23(9):1117–1125
   PubMed Web of Science ®Google Scholar
• . Weiner LM. Fully human therapeutic monoclonal antibodies. J Immunother. 2006;29(1):1–9
   PubMed Web of Science ®Google Scholar
• . Jang G, Peterson M. Denosumab an inhibitor of RANKL has pharmacokinetics similiar to other monoclonal antibodies. J Bone Miner Res. 2006;21( suppl 1). http://www.abstractsonline.com/viewer/searchAdvanced.asp?MKey={FC197A55-D8DD-4F3D-9994-290B64584CCB}&AKey={D0C01D4F-E23B-45E2-ACD4-0AF8AC866B8B}. Accessed July 15, 2010
   Web of Science ®Google Scholar
• . Peterson M, Stouch B, Martin S. The pharmacokinetics of denosumab (AMG162) following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res. 2005;20( suppl 1). http://www.abstractsonline.com/viewer/?mkey=%7B70A6304C%2DA41B%2D49FC%2DA4DF%2DC147A5E943F0%7D%20. Accessed July 15, 2010
   Web of Science ®Google Scholar
• . McClung MR, Lewiecki EM, Cohen SB, . Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354(8):821–831
   PubMed Web of Science ®Google Scholar
• . Cummings SR, San Martin J, McClung MR, ; FREEDOM trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361(8):756–765
   PubMed Web of Science ®Google Scholar
• . Boonen S, McClung M, Minisola S, . Effect of denosumab on the incidence of hip, new vertebral, and nonvertebral fractures over 3 years among postmenopausal women with higher fracture risk: a subgroup analysis from the FREEDOM study. J Bone Miner Res. 2009;24( suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts09.aspx. Accessed July 15, 2010
   Google Scholar
• . Bone H, Bolognese MA, Yuen CK, . Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Bone Miner Res. 2009;24( suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts09.aspx. Accessed July 15, 2010
   PubMed Web of Science ®Google Scholar
• . Miller PD, Bolognese MA, Lewiecki EM, ; AMG 162 Bone Loss Study Group. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222–229
   PubMed Web of Science ®Google Scholar
• . Kendler DL, Roux C, Benhamou CL, . Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010;25(1):72–81
   PubMed Web of Science ®Google Scholar
• . Brown JP, Prince RL, Deal C, . Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res. 2009;24(1):153–161
   PubMed Web of Science ®Google Scholar
• . Bone HG, Bolognese MA, Yuen CK, . Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008;93(6):2149–2157
   PubMed Web of Science ®Google Scholar
• . Riggs BL, Wahner HW, Dunn WL, Mazess RB, Offord KP, Melton LJ 3rd. Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest. 1981;67(2):328–335
   PubMed Web of Science ®Google Scholar
• . Zebaze RM, Ghasem-Zadeh A, Bohte A, . Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375(9727):1729–1736
   PubMed Web of Science ®Google Scholar
• . Seeman E, Delmas PD, Hanley DA, . Microarchitectural deterioration of cortical and trabecular bone: differing effects of denosumab and alendronate. J Bone Miner Res. 2010;25(8):1886–1894
   PubMed Web of Science ®Google Scholar
• . Miller PD, Bolognese MA, Lewiecki EM, . Effects of denosumab on bone mineral density and biochemical markers of bone turnover: 6 year results of a phase 2 clinical trial. J Bone Miner Res. 2009;24( suppl 1). http://www.asbmr.org/Meetings/AnnualMeeting/Abstracts09.aspx. Accessed July 15, 2010
   Google Scholar
• . Kendler DL, Bessette L, Hill CD, . Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int. 2010;21(5):837–846
   PubMed Web of Science ®Google Scholar
• . Papapoulos S, Bone HG, Brandi ML, . Four years of denosumab exposure in women with postmenopausal osteoporosis: results from the first year extension of the FREEDOM trial. Presented at: The American Society of Bone and Mineral Research; October 15–19, 2010; Toronto, Canada
   Google Scholar
• . Fosamax® (alendronate sodium) [package insert]. Whitehouse Station, NJ: Merck and Co Inc; 2008
   Google Scholar
• . Pols HA, Felsenberg D, Hanley DA, . Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int. 1999;9(5):461–168
   PubMed Web of Science ®Google Scholar
• . Boniva® Injection (ibandronate sodium) [package insert]. Nutley, NJ: Roche Laboratories, Inc; 2009
   Google Scholar
• . Boniva® tablets (ibandronate sodium) [package insert]. Nutley, NJ: Roche Laboratories, Inc; 2010
   Google Scholar
• . Actonel® (risedronate sodium) [package insert]. Cincinnati, OH: Procter and Gamble Pharmaceuticals, Inc; 2009
   Google Scholar
• . McClung MR, Geusens P, Miller PD, . Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333–340
   PubMed Web of Science ®Google Scholar
• . Reclast® (zoledronic acid) [package insert]. East Hanover, NJ: Novartis Pharmaceutical Corp; 2009
   Google Scholar
• . Evista® (raloxifene hydrochloride) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2008
   Google Scholar
• . Fortical® (calcitonin-salmon) [package isnert]. Minneapolis, MN: Upsher-Smith Laboratories, Inc; 2009
   Google Scholar
• . Chesnut CH 3rd, Silverman S, Andriano K, . A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000;109(4):267–276
   PubMed Web of Science ®Google Scholar
• . Forteo® (teriparatide) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009
   Google Scholar